ArticlePediatric nephrology (Berlin, Germany)2021
Biopsy-proven Henoch-Schönlein purpura nephritis: a single center experience.
Article in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication.Clinical and experimental nephrology · 2026Review
- The association between fractalkine/CX3CR1 axis with IgA vasculitis and nephritis.Pediatric research · 2026Article
- Correlation between the course of kidney injury and clinicopathology and prognosis of children with Henoch-Schönlein purpura nephritis.International urology and nephrology · 2025Article
- Biomarker research for Henoch-Schönlein purpura nephritis based on "omics" techniques.Frontiers in medicine · 2025Review
- Clinicopathological features and prognosis of IgA vasculitis nephritis with nephrotic-range proteinuria in children.Pediatric nephrology (Berlin, Germany) · 2024Article
- Proanthocyanidins alleviate Henoch-Schönlein purpura by mitigating inflammation and oxidative stress through regulation of the TLR4/MyD88/NF-κB pathway.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Long-term Results in Children with Henoch-Schönlein Nephritis.Medeniyet medical journal · 2022Article
- Timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2022Article
- Response to: Timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA Vasculitis Nephritis.Pediatric nephrology (Berlin, Germany) · 2022Article
- Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.Frontiers in pharmacology · 2022Review
- Epidemiology of biopsy-proven Henoch-Schönlein purpura nephritis in children: A nationwide survey in Japan.PloS one · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnowledge on normal progress and treatment of Henoch-Schönlein purpura nephritis (HSPN) is limited. This study reviews outcome, clinical, pathological, and therapeutic factors affecting the prognosis of HSPN patients.
methodsForty-nine children with biopsy-confirmed HSPN diagnosed between September 2008 and 2018 were included. Demographics, clinical and laboratory data, treatment, and outcome were recorded at the time of biopsy, 3, 6, 12, and 24 months and at last visit. Clinical outcome was graded according to Meadow's criteria.
resultsThe median age at time of biopsy was 10.1 years (IQR:5.7) and female/male ratio 24/25. At presentation, 40.8% of patients had nonnephrotic proteinuria, 18.4% nephrotic syndrome (NS), 4.1% nephritic syndrome (NephrS), and 36.7% NephrS+NS. There were 11 patients with an estimated glomerular filtration rate below 90 ml/min/1.73 m
conclusionA large proportion of patients continued to show signs of CKD at last follow-up while only a small proportion developed stage 5 CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.